CHRM3 and cancer: ARHGEF7 and CHRM3 were overexpressed two-fold or greater in eight (47%) and 12 (71%) cancers, respectively; ARHGEF7 and CHRM3 were both over-expressed in seven of 17 cancers (41%; Fig. 2b/c).